# CASI Pharmaceuticals, Inc. (CASIF)

> Source: Nexqual · https://nexqual.com/CASIF · data as of 2026-10-23 17:43 UTC · cite as "Nexqual, CASI Pharmaceuticals, Inc. (CASIF), nexqual.com/CASIF" · informational, not investment advice.

**Price:** USD 0.1 (+0.15% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0.1 · day 0.1–0.1 · 52w 0.05–1.77 · market cap $2.1M · OQB

## Key facts
- Total return with dividends: 1Y -93.9% vs S&P 500 +13.4%; 5Y -99.1% vs S&P 500 +76.9%.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -93.9% | -99.1% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -94.0% | -60.8% |
| Volatility (annualized) | 225.1% | 110.2% |
| Max drawdown | -93.9% (Oct 2025→Jun 2026) | -99.1% (Nov 2021→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/CASIF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CASIF's own 20-F filed 2026-05-15 (https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Spectrum Pharmaceuticals | "We had a supply agreement with Spectrum to support our application for import drug registration and for commercialization purposes." |
| Supplier | Resources Pharmaceutical Commercial Group International Trading | "We rely on one single distributor, CRPCGIT for the distribution of EVOMELA® and CNMC for the distribution of FOLOTYN®." |
| Supplier | China National Medicines Corporation | "We rely on one single distributor, CRPCGIT for the distribution of EVOMELA® and CNMC for the distribution of FOLOTYN®." |
| Partner | Acrotech Biopharma | "In July 2023, we entered into a tripartite assignment agreement with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo") and Acrotech, pursuant to which, MICL's rights and obligat…" |
| Partner | Mundipharma International Corporation | "In July 2023, we entered into a tripartite assignment agreement with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo") and Acrotech, pursuant to which, MICL's rights and obligat…" |
| Partner | Guangzhou Gloria Biosciences | "In January 2025, we entered into a three-year distribution agreement with Guangzhou Gloria Biosciences Co., Ltd., pursuant to which CASI China was appointed as a non-exclusive distributor for the sales of YuTuo® in China…" |
| Partner | ETP Global III Fund | "On December 11, 2025, we entered into a convertible note purchase agreement (the "Purchase Agreement") with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He (the "Purchaser"), pursuant to which the Compa…" |
| Partner | Cleave Therapeutics | "On July 18, 2023, we entered into an assignment agreement with Cleave, pursuant to which we obtained the global intellectual property rights related to CB-5339." |
| Partner | Juventas Cell Therapy | "CNCT19 is an autologous CD19 CAR-T investigative product (CNCT19) being developed by our partner Juventas for which we have exclusive worldwide co-commercial and profit-sharing rights." |
| Partner | Precision Autoimmune Therapeutics | "Other operating income for the year ended December 31, 2023, were US$6.4 million, mainly consisted of a US$4.4 million reimbursement from PAT for certain labor cost and certain pre-clinical and clinical service incurred …" |
| Partner | Human Longevity | "In December 2024, we entered into a service agreement with Human Longevity Inc. ("HLI"), pursuant to which CASI will use certain of HLI's office facilities at a service charge of $8,000 per month." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-03-31) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |